FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1591-1592 April 12, 2007 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Encouraging results have led to the use of temozolomide as a first-line therapy for glioblastoma.¹ We report on a case of temozolomide-associated reactivation of hepatitis B, a complication that may warrant the use of prophylactic antiviral agents during treatment with this chemotherapy.²

A 65-year-old Chinese woman with a remote history of hepatitis B underwent total surgical resection of an enhancing mass in the left temporal lobe, which was diagnosed as glioblastoma. She received radiation therapy with concurrent daily temozolomide (at a dose of 75 mg per square meter of body-surface area), followed by three cycles of adjuvant . . . [Full Text of this Article]

This article has been cited by other articles:

• Torresin, A., Feasi, M., Cassola, G. (2008). Hepatitis B reactivation prophylaxis in immune-suppressed patients. haematol 93: e65-e65 [Full Text]  
• Torresin, A, Feasi, M, Cassola, G (2007). Hepatitis B serological evaluation in diagnostic work up of lymphoma. Ann Oncol 18: 1284-1284 [Full Text]